Multiple Myeloma Hub cover art

Multiple Myeloma Hub

Multiple Myeloma Hub

By: Scientific Education Support
Listen for free

This Season's Biggest Deal | $0.99/mo for 3 months + $20 Audible bonus

Auto-renews at $8.99/mo. after 3 months - terms apply.
Summary
The Multiple Myeloma Hub is an open-access online resource, dedicated to providing balanced, credible, and up-to-date medical education in multiple myeloma. Our aim is to enhance knowledge in multiple myeloma, through the multichannel dissemination of global advances related to their classification, diagnosis, treatment, and management.

Hosted on Acast. See acast.com/privacy for more information.

Scientific Education Support
Episodes
  • What is on the horizon for BCMA-directed ADCs in MM?
    Nov 17 2026

    The Multiple Myeloma Hub spoke with Marc Raab, Heidelberg University Hospital, DE. We asked, What is on the horizon for BCMA-directed antibody–drug conjugates in multiple myeloma?


    In this interview, Raab discusses the ongoing development of belantamab mafodotin in additional combination regimens and earlier lines of therapy, as well as investigational antibody–drug conjugates (ADCs) incorporating alternative cytotoxic payloads or targeting other antigens. Raab also explores the potential role of ADC-based regimens for patients who are ineligible for, or have previously received, chimeric antigen receptor (CAR) T-cell therapy or bispecific antibodies.


    This educational resource is independently supported by GSK. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.

    Hosted on Acast. See acast.com/privacy for more information.

    Show More Show Less
    7 mins
  • Targeting FcRH5 in MM: Rationale and emerging dual-targeting strategies
    Oct 12 2026

    The Multiple Myeloma Hub was pleased to speak with Adam Cohen, University of Pennsylvania, Philadelphia, US. We asked about the rationale for targeting FcRH5 in multiple myeloma and emerging dual-targeting strategies.


    In this interview, Cohen discusses Fc receptor-homolog 5 (FcRH5) as a therapeutic target in multiple myeloma (MM) and its potential role following antigen loss associated with B-cell maturation antigen (BCMA)- or G protein-coupled receptor class C group 5 member D (GPRC5D)-directed therapy. Cohen outlines the rationale for targeting multiple antigens, the potential benefits and challenges of dual-targeting, and which patients may benefit most from these approaches. Cohen also reviews emerging data on the FcRH5-targeted bispecific antibody cevostamab, including its evaluation as monotherapy and as part of combination and sequential treatment strategies.


    Intended for healthcare professionals. This educational resource is independently supported by Roche. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.

    Hosted on Acast. See acast.com/privacy for more information.

    Show More Show Less
    7 mins
  • IMS 2026 | CARTITUDE-2 Cohort A: ≥5-year remission and survival with cilta-cel in RRMM
    Oct 8 2026

    During the 23rd International Myeloma Society (IMS) Annual Meeting and Exposition, September 23–26, 2026, Glasgow, UK, the Multiple Myeloma Hub spoke with María-Victoria Mateos, University Hospital of Salamanca, ES. We asked about the long-term outcomes with ciltacabtagene autoleucel (cilta-cel) in patients with relapsed/refractory multiple myeloma (RRMM) in Cohort A of the CARTITUDE-2 trial.


    In this interview, Mateos discusses the ≥5-year findings from Cohort A of the phase II CARTITUDE-2 trial (NCT04133636), which evaluated a single cilta-cel infusion in patients with RRMM after 1–3 prior lines of therapy who were exposed to a proteasome inhibitor and are lenalidomide-refractory. Mateos reviews long-term remission and survival outcomes, characteristics associated with prolonged disease control, immune correlates of durable response, and long-term safety findings. Mateos also discusses these findings in the context of cilta-cel use in earlier lines of therapy.

    Hosted on Acast. See acast.com/privacy for more information.

    Show More Show Less
    6 mins
No reviews yet
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.